syyskuu 21

Kliinisen patologian nykynäkymiä: Antti Sajantila

​Antti Sajantila: Oikeustieteen ja patologian yhteistyömahdollisuudet H3:ssa

Aloitusaika: 21.09.2021 12:15
Lopetusaika: 21.09.2021 13:00
Kesto: 45 minutes
Sijainti: Patologian kirjasto (C-porras, 2. krs), Haartmaninkatu 3, 00290 Helsinki
Tyyppi: Seminar
Organisaatio: UH, Faculty of Medicine
syyskuu 21

Kliinisen kemian seminaari: Päivi Laitinen

​Päivi Laitinen: Kilpailutuksen hyvät käytännöt
Aloitusaika: 21.09.2021 14:15
Lopetusaika: 21.09.2021 15:00
Kesto: 45 minutes
Sijainti: remotely
Tyyppi: Seminar
Organisaatio: UH, Faculty of Medicine
Yhteyshenkilö: tuukka.helin@helsinki.fi
syyskuu 21

BiotechClub Bayer Event

We at BiotechClub are thrilled to start the new academic year with an exciting online BiotechClub Bayer Event! In this event you will have an unique opportunity to glimpse at the life in Bayer. Presenters will talk about Bayer´s mission and vision, explain how pharma industry works in Finland and give you a sense of how it is to work for Bayer. Moreover, we promise a panel discussion about importance of sustainability! This event is sponsored by DSHealth and Oyj Aiforia Technologies.
Preliminary program:
21st of September at 15:00 – 16:30 via Zoom

Pitch: BiotechClub Aims & Activities:

                          Darshan Kumar, PhD. (Board member BiotechClub)

Bayer Mission and Vision:

                          Miriam Holstein (CEO, Bayer Nordic Region)

How does the pharma industry work in Finland: what kind of jobs are there and how do I get noticed.

                          Tarja Jalava, PhD (Director, Clinical Project Management II, Oncology Strategic Business Unit)

Pitches (3 * 5 min): Life at Bayer:

                          Markus Lindqvist, PhD (Study Manager)

                          Martin Pushkarjov, PhD, Docent (Scientific Medical Writer)

                          Sasa Kivisaari, PhD (Principal Clinical Data Engineer)

Panel Discussion (15min): Importance of innovation & collaboration, sustainability, diversity & inclusion in today’s world.

You can register to this event via (https://elomake.helsinki.fi/lomakkeet/113085/lomake.html) by the 19th of September. Please note that there are limited seats for this event. Registration will be on first come first serve basis.
We are looking forward to seeing you!

Aloitusaika: 21.09.2021 15:00
Lopetusaika: 21.09.2021 16:30
Kesto: 1 hour 30 minutes
Sijainti: remotely
Tyyppi: Other
Organisaatio: BiotechClub
syyskuu 25

Dissertation: Max Åström

​Max Åström, Faculty of Medicine, Doctoral Programme in Population Health
Physical performance in older adults: Association with glucose regulation and telomere length

Opponent: professor Sakari Suominen, University of Turku


Aloitusaika: 25.09.2021 12:00
Lopetusaika: 25.09.2021 14:00
Kesto: 2 hours
Sijainti: Porthania PII, Yliopistonkatu 3, Helsinki
Tyyppi: Dissertation
Organisaatio: UH, Faculty of Medicine
Yhteyshenkilö: max.astrom@helsinki.fi
syyskuu 27

HiLIFE Webinar: Mart Saarma: From DNA diagnostics to drug development company – My personal journey

Mart Saarma is the Research Director and head of the laboratory at the Institute of Biotechnology, HiLIFE, University of Helsinki. He was in 2015-2016 the Vice President of the European Research Council and in 2011-2016 the member of the EMBO Council. He is the member of several academies, EMBO and Academia Europea. Dr. Saarma group has characterized several new GDNF family receptors, discovered a new neurotrophic factor CDNF. His research group is investigating the signalling and biological functions of GDNF family ligands and endoplasmic reticulum located CDNF/MANF neurotrophic factor families, both within and outside of the nervous system. He is also interested in the therapeutic potential of these proteins in various diseases, so he is testing their efficacy in animal models of Parkinson's disease, amyotrophic lateral sclerosis, stroke and diabetes mellitus. One of the highlights of his research has been initiation and successful completion of phase I-II clinical trials of CDNF protein in Parkinson's disease patients by the Finnish company Herantis Pharma Plc. He was also a founder of Mobidiag Ltd. company that was recently sold to Hologic company.
In this talk, Prof. Saarma will relate his personal journey of combining cutting-edge biomedical research with entrepreneurial activities, to bring his discoveries to society.
Welcome to this exciting seminar!  
Chiara Facciotto
Selected publications
Lindholm, P., Voutilainen, M .H., Laurén, J., Peränen, J., Leppänen, V-M., Andressoo, J.-O., Lindahl, M., Janhunen, S.,  Kalkkinen, N., Timmusk, T., Tuominen, R. K. and Saarma, M. (2007) Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature, 448, 73-77.
Kopra, J, Vilenius, C, Grealish, S, Harma, M-A, Varendi, K, Lindholm, J, Castren, E, Voikar, V, Bjorklund, A, Piepponen, T. P, Saarma, M*, Andressoo, J-O*. (2015) GDNF is not required for catecholaminergic neuron survival in vivo. Nature Neuroscience 18 (3): 319-322. * Equal contribution.
Mahato AK, Kopra J, Renko JM, Visnapuu T, Korhonen I, Pulkkinen N, Bespalov MM, Domanskyi A, Ronken E, Piepponen TP, Voutilainen MH, Tuominen RK, Karelson M, Sidorova YA, Saarma M. (2020) Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in vitro and enhances dopamine release in vivo. Movement Disorders. 35(2):245-255. doi: 10.1002/mds.27943. Epub 2019 Dec 16. PMID:31840869
Casarotto PC, Girych M, Fred SM, Kovaleva V, Moliner R, Enkavi G, Biojone C, Cannarozzo C, Sahu MP, Kaurinkoski K, Brunello CA, Steinzeig A, Winkel F, Patil S, Vestring S, Serchov T, Diniz CRAF, Laukkanen L, Cardon I, Antila H, Rog T, Piepponen TP, Bramham CR, Normann C, Lauri SE, Saarma M, Vattulainen I, Castrén E (2021) Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021 Feb 18:S0092-8674(21)00077-5. doi: 10.1016/j.cell.2021.01.034. Online ahead of print.PMID: 33606976  
Jasmin M, Ahn EH, Voutilainen MH, Fombonne J, Guix C, Viljakainen T, Kang SS, Yu LY, Saarma M*, Mehlen P*, Ye K.* (2021) Netrin-1 and its receptor DCC modulate survival and death of dopamine neurons and Parkinson's disease features. EMBO J. 2021 Feb 1;40(3):e105537. doi: 10.15252/embj.2020105537. Epub 2020 Dec 22.PMID: 33351190. * Shared senior authors  

Aloitusaika: 27.09.2021 12:00
Lopetusaika: 27.09.2021 13:00
Sijainti: remotely
Tyyppi: Webinar
Organisaatio: UH, Faculty of Medicine
Yhteyshenkilö: hilife-seminars@helsinki.fi